Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AbbVie Seeks Crohn’s Disease Nod for Skyrizi in Japan
November 15, 2021
- Eylea Filed for ROP in Premature Babies in Japan, EU: Bayer
November 15, 2021
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Seikagaku to Launch Clinical Research to Verify Cause of Anaphylaxis after Blue Letter
November 15, 2021
- AstraZeneca’s Japan Healthcare Innovation Hub Grows to 131 Members
November 12, 2021
- Rohto Wants to Wrap Up PII of COVID-19 Cell Therapy in 2022: President
November 12, 2021
- Choseido Resumes Operations after 31-Day Biz Suspension
November 12, 2021
- Over 500 Suzuken Group Staffers Take Voluntary Redundancy
November 12, 2021
- Aikomi, Sumitomo Dainippon Eye Therapeutic App Approval for BPSD by 2027
November 12, 2021
- Chugai Files for Additional Indication for Hemlibra in Japan
November 12, 2021
- Nippon Shinyaku Inks Option Pact for Dynacure’s Antisense in Japan
November 11, 2021
- Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
- Otsuka, Takara Bio to Call Off Collaboration for Two Drug Candidates
November 10, 2021
- MSD Launches Antibiotic Recarbrio in Japan
November 10, 2021
- 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
- Japan Ethical Drug Sales Rise 4.0% in September: Crecon
November 9, 2021
- Lilly, Torii to Wind Up Taltz Marketing Collaboration in Japan
November 9, 2021
- Ono’s BTK Inhibitor Velexbru Approved in South Korea
November 9, 2021
- Takecab Top-Seller Medicine in Japan in October: Encise
November 8, 2021
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…